Merck, Moderna and melanoma

Digest more
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Pharmaceutical giants Moderna and Merck said Wednesday that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients...

Continue reading

Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
Moderna, Merck See Promise in Experimental Skin Cancer Vaccine
New drug therapy shown to prevent recurrence of melanoma in study
A trial of more than 1,100 patients finds a new experimental drug could prevent melanoma, one of the deadliest forms of skin cancer, from returning.

Continue reading

Personalised melanoma vaccine shows ‘clinically meaningful’ results in major trial
New Scientist · 8h
Will personalised mRNA vaccines transform cancer treatments?
From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
Moderna and the big drugmaker Merck reported that their experimental cancer vaccine extended the time before melanoma recurred in a clinical trial — the first late-stage study of its kind to succeed.

Continue reading

Skin cancer breakthrough after experimental mRNA drug found to prevent disease returning
Moderna and Merck Revive mRNA Hopes With Melanoma Trial Success
BioSpace

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.

Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna (MRNA)-partnered cancer shot. Read more here.

Moderna, Merck, SK Hynix, Micron, Target, Estée Lauder, and More Stocks That Explain Today’s Market

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.
24/7 Wall St.

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121.76 in early Wednesday trading after the company and partner Merck (NYSE:MRK) announced that their Phase 3 melanoma trial met its primary endpoint.